#Australia #Woburn #Micro-Coring Technology #Australian Aesthetics #Cytrellis Biosystems

Cytrellis Launches ellacor® Micro-Coring® Technology in Australia

Cytrellis Biosystems, Inc. has made a significant leap in the aesthetics medical field with the launch of its revolutionary ellacor® Micro-Coring Technology in Australia. Following the approval from Australia's Therapeutic Goods Administration, this innovation promises to reshape the landscape of skin health and restoration for practitioners and patients alike.

A Significant Milestone

This approval marks a pivotal point in Cytrellis' journey as it expands its internationally recognized Micro-Coring Technology through Device Consulting Pty. Ltd. This launch provides Australian physicians with access to a groundbreaking method that effectively treats skin laxity and enhances skin quality by removing small micro-cores of skin tissue without the need for surgical procedures.

Denise Dajles, CEO of Cytrellis, expressed her enthusiasm, stating, "This approval represents another major milestone in our mission to redefine what's possible in skin health and restoration. As demand for non-surgical solutions continues to grow worldwide, we are proud to introduce ellacor's unique Micro-Coring Technology to practitioners and patients throughout Australia."

Versatility in Treatment Areas

Originally developed to tackle moderate to severe wrinkles and excess skin on the face, ellacor® has evolved into a versatile platform that can address multiple body areas. With the recent approval, Australian physicians are now empowered to perform full-body resurfacing procedures, enhancing skin quality in regions such as the neck, abdomen, arms, thighs, and knees. This comprehensive approach signifies a step forward in aesthetics, allowing for more tailored treatments.

Unlike traditional energy-based treatments, ellacor® removes tiny micro-cores of the skin while preserving surrounding tissues. This technique not only stimulates the body's natural healing response but also promotes collagen remodeling. The outcome is visibly smoother, firmer skin with minimal recovery time, offering patients a less invasive option without the risks of scarring or thermal injury typically associated with conventional methods.

Growing Demand for Non-Surgical Solutions

According to Milivoj Boltuzic, CEO of Device Consulting, the Australian aesthetics market is increasingly gravitating towards technologies supported by robust clinical evidence and proven patient outcomes. The launch of ellacor® is timely given the rising demand for non-surgical procedures that effectively address challenges such as loose skin, often caused by aging, weight fluctuations, or the impact of medical treatments like GLP-1 medications.

Professor Greg Goodman, an esteemed dermatologist, highlighted the importance of this new option, stating, "The ability to remove excess skin without surgery or thermal energy provides physicians with an entirely new treatment avenue. Patients are searching for effective solutions that require less downtime and deliver natural results. The Micro-Coring Technology of ellacor could significantly impact aesthetic medicine, changing how we approach skin rejuvenation for both face and body."

Future Prospects for Cytrellis

The approval and launch of ellacor® in Australia represent a critical step in Cytrellis' broader strategy for international expansion. By continuing to introduce innovative technologies globally, Cytrellis seeks to build momentum and enhance its presence in the aesthetics market. As clinical adoption grows and regulatory approvals expand, the company remains focused on developing evidence-based innovations that restore skin health naturally, ensuring patients achieve significant and long-lasting results without resorting to invasive surgery.

To learn more about ellacor® and Cytrellis, visit www.ellacor.com or www.cytrellis.com.

About Cytrellis Biosystems

Cytrellis Biosystems is at the forefront of medical aesthetics, dedicated to advancing skin health and restoration through evidence-based solutions. Its flagship product, ellacor®, featuring Micro-Coring Technology, represents the only FDA-cleared non-surgical treatment that removest excess skin to address moderate and severe wrinkles. For further details, visit www.cytrellis.com and connect with them on social media platforms.

About Device Consulting

Device Consulting operates as a premier distributor of advanced medical aesthetic and surgical technologies across Australia and New Zealand, partnering with global innovators to provide clinicians with clinically proven solutions. Visit www.deviceconsulting.com.au for more information.